However, the effect of the PKCβ-specific inhibitor, LY333531, has been investigated in experimental research and clinical trials for the treatment of retinal vascular diseases, including retinal vein occlusion and diabetic retinopathy, but the results have not been as promising as hoped [16,30,31]. This evidence concerns the gene PRKCB and retinal vein occlusion.